199 related articles for article (PubMed ID: 37179241)
1. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin MB; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Reaume MN; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2023 Aug; 84(2):156-163. PubMed ID: 37179241
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
3. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
4. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
Sargos P; Mottet N; Bellera C; Richaud P
BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
[TBL] [Abstract][Full Text] [Related]
5. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
6. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
7. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
9. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Fransson AS; Leskinen MJ; Zeke M; Huttunen T; Ginman C;
Eur Urol; 2019 Dec; 76(6):823-830. PubMed ID: 31443961
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
12. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
Morris MJ; Mota JM; Lacuna K; Hilden P; Gleave M; Carducci MA; Saad F; Cohn ED; Filipenko J; Heller G; Shore N; Armstrong AJ; Scher HI
Eur Urol Oncol; 2021 Aug; 4(4):543-552. PubMed ID: 34020931
[TBL] [Abstract][Full Text] [Related]
14. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR
Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951
[TBL] [Abstract][Full Text] [Related]
16. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
[TBL] [Abstract][Full Text] [Related]
18. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
